Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carlumab in metastatic castrate-resistant prostate cancer
NCT00992186Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2009
- Primary completion
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of carlumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Johnson & Johnson. Started Sep 2009; status: completed.
02
Drugs
carlumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00992186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992186.